SecBot SecBot
SECBOTREPLAY Home › Report › CRVS

CRVS · Corvus Pharmaceuticals will host an investor meeting on May 14, 2026,…

Corvus Pharmaceuticals, Inc. · PRESS-RELEASE filed Apr 21, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 21, 2026 at 07:30 ET

Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clinical data for soquelitinib in atopic dermatitis, including late-breaking data on drug-free remissions, presented at the Society for Investigative Dermatology meeting. The company will report Q1 2026 financial results on May 7 but will not hold a conference call.

  • Investor and analyst meeting scheduled for May 14, 2026, to discuss soquelitinib Phase 1 data from the SID Annual Meeting.
  • Two oral presentations at SID include a late-breaking session on drug-free remissions with soquelitinib.
  • Phase 1 trial data is from a randomized, blinded, placebo-controlled study in moderate-to-severe atopic dermatitis.
  • Company to release Q1 2026 financial results on May 7, 2026, without a conference call or webcast.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access